{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:45:04Z","timestamp":1776386704588,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucocorticoid treatment is used in children with Graves\u2019 disease (GD) only in cases of exophthalmos. The purpose of this study was to observe the effects of glucocorticoid pulse therapy on thyroid function and thyroid antibodies in children with GD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty children who were treated by intravenous methylprednisolone pulse therapy (MPT) followed by oral prednisolone administration and antithyroid drugs were included in the pulse group. Twenty children who were treated with antithyroid drugs alone were included in the control group. Serum concentrations of free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TGAb), and thyrotropin receptor antibodies (TRAb) were recorded at baseline and 10\u2009days, 30\u2009days, and 60\u2009days after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significant differences in FT3, FT4, TSH, TPOAb, TGAb, and TRAb levels were found in the pulse group and the control group from baseline to follow-up time points (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). On the 30th day, the TRAb level in the pulse group was significantly lower than that in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023). However, the level of TRAb rose on the 60th day. For values of TRAb at baseline, 10\u2009days, and 60\u2009days after treatment, there were no significant differences respectively between the pulse group and the control group (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). No significant differences were observed in FT3, FT4, TSH, TPOAb, and TGAb levels between the pulse group and the control group (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results suggested that the effect of intravenous MPT followed by oral prednisolone on TRAb level was temporary in children with GD. Glucocorticoid pulse therapy was not beneficial for the sustained recovery of thyroid function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-021-00999-5","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T07:05:28Z","timestamp":1614668728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of glucocorticoid pulse therapy on thyroid function and thyroid antibodies in children with graves\u2019 disease"],"prefix":"10.1186","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6444-8961","authenticated-orcid":false,"given":"Yanyan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4231-5639","authenticated-orcid":false,"given":"Yulin","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-7292","authenticated-orcid":false,"given":"Xuemei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3495-6732","authenticated-orcid":false,"given":"Yongzhen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"999_CR1","first-page":"66","volume":"68","author":"F De Luca","year":"2016","unstructured":"De Luca F, Alessi L, Bruno E, Cama V, Costanzo D, Genovese C, et al. Graves\u2019 disease in childhood: new epidemiological, pathophysiological and therapeutic insights. Minerva Pediatr. 2016;68:66\u20139.","journal-title":"Minerva Pediatr"},{"key":"999_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000430985","volume":"84","author":"RH Kj\u00e6r","year":"2015","unstructured":"Kj\u00e6r RH, Andersen MS, Hansen D. Increasing incidence of juvenile thyrotoxicosis in Denmark:a nationwide study, 1998-2012. Horm Res Paediatr. 2015;84:102\u20137.","journal-title":"Horm Res Paediatr"},{"key":"999_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1530\/EJE-09-0751","volume":"162","author":"F De Luca","year":"2010","unstructured":"De Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, Cassio A, et al. Peculiarities of Graves' disease in children and adolescents with Down's syndrome. Eur J Endocrinol. 2010;162:591\u20135.","journal-title":"Eur J Endocrinol"},{"key":"999_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000357130","volume":"81","author":"M Valenzise","year":"2014","unstructured":"Valenzise M, Aversa T, Corrias A, Mazzanti L, Cappa M, Ubertini G, et al. Epidemiology, presentation and long-term evolution of Graves' disease in children, adolescents and young adults with turner syndrome. Horm Res Paediatr. 2014;81:245\u201350.","journal-title":"Horm Res Paediatr."},{"key":"999_CR5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1089\/thy.2013.0452","volume":"24","author":"T Aversa","year":"2014","unstructured":"Aversa T, Lombardo F, Corrias A, Salerno M, De Luca F, Wasniewska M. In young patients with turner or Down syndrome, Graves' disease presentation is often preceded by Hashimoto\u2019s thyroiditis. Thyroid. 2014;24:744\u20137.","journal-title":"Thyroid."},{"key":"999_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000313395","volume":"73","author":"M Wasniewska","year":"2010","unstructured":"Wasniewska M, Corrias A, Arrigo T, Lombardo F, Salerno M, Mussa A, et al. Frequency of Hashimoto's thyroiditis antecedents in the history of children and adolescents with graves' disease. Horm Res Paediatr. 2010;73:473\u20136.","journal-title":"Horm Res Paediatr."},{"key":"999_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1542\/pir.36-6-239","volume":"36","author":"S Srinivasan","year":"2015","unstructured":"Srinivasan S, Misra M. Hyperthyroidism in children. Pediatr Rev. 2015;36:239\u201348.","journal-title":"Pediatr Rev"},{"key":"999_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1530\/eje.1.01991","volume":"153","author":"GE Krassas","year":"2005","unstructured":"Krassas GE, Segni M, Wiersinga WM. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol. 2005;153:515\u201321.","journal-title":"Eur J Endocrinol"},{"key":"999_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/ijerph16010155","volume":"16","author":"L Penta","year":"2019","unstructured":"Penta L, Muzi G, Cofini M, Leonardi A, Lanciotti L, Esposito S. Corticosteroids in moderate-to-severe Graves' Ophthalmopathy: Oral or intravenous therapy? Int J Environ Res Public Health. 2019;16:155.","journal-title":"Int J Environ Res Public Health"},{"key":"999_CR10","first-page":"462","volume":"36","author":"Z Mingzhi","year":"2000","unstructured":"Mingzhi Z, Rongzhao H, Zhifu FU. The measurement of normal values of exophthalmos, interpupillary distance and interorbital distance of children and adolescence in Xiamen and the rule of their development. Chin J Ophthalmol. 2000;36:462.","journal-title":"Chin J Ophthalmol"},{"key":"999_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/thy.2010.0417","volume":"21","author":"RS Bahn Chair","year":"2011","unstructured":"Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593\u2013646.","journal-title":"Thyroid."},{"key":"999_CR12","unstructured":"WHO U. Assessment of the iodine deficiency disorders and monitoring their elimination. Geneva. 2001:1\u2013107."},{"key":"999_CR13","doi-asserted-by":"publisher","first-page":"544658","DOI":"10.3389\/fendo.2020.544658","volume":"11","author":"B Sawicka","year":"2020","unstructured":"Sawicka B, Borysewicz-Sa\u0144czyk H, Wawrusiewicz-Kurylonek N, Aversa T, Corica D, Go\u015bcik J, et al. Analysis of Polymorphisms rs7093069-IL-2RA, rs7138803-FAIM2, and rs1748033-PADI4 in the Group of Adolescents With Autoimmune Thyroid Diseases. Front Endocrinol (Lausanne). 2020;11:544658.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"999_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.endonu.2016.04.003","volume":"63","author":"AM Ramos-Lev\u00ed","year":"2016","unstructured":"Ramos-Lev\u00ed AM, Marazuela M. Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol Nutr. 2016;63:421\u20139.","journal-title":"Endocrinol Nutr"},{"key":"999_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13044-018-0046-9","volume":"11","author":"M Rydzewska","year":"2018","unstructured":"Rydzewska M, Jaromin M, Pasierowska IE, Sto\u017cek K, Bossowski A. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res. 2018;11:2.","journal-title":"Thyroid Res"},{"key":"999_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"BS Prabhakar","year":"2003","unstructured":"Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of graves\u2019 disease and ophthalmopathy. Endocr Rev. 2003;24:802\u201335.","journal-title":"Endocr Rev"},{"key":"999_CR17","first-page":"90","volume":"11","author":"S Zang","year":"2011","unstructured":"Zang S, Kahaly GJ. Steroids and the immune response in Graves\u2019 orbitopathy. Agents Med Chem. 2011;11:90\u20138.","journal-title":"Agents Med Chem"},{"key":"999_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2249.2004.02750.x","volume":"140","author":"G Kahaly","year":"2005","unstructured":"Kahaly G, Bang H, Berg W, Dittmar M. Alpha-fodrin as a putative autoantigen in graves\u2019 ophthalmopathy. Clin Exp Immunol. 2005;140:166\u201372.","journal-title":"Clin Exp Immunol"},{"key":"999_CR19","doi-asserted-by":"crossref","unstructured":"Tu X, Dong Y, Zhang H, Su Q. Corticosteroids for Graves' Ophthalmopathy: systematic review and meta-analysis. Biomed Res Int. 2018:4845894.","DOI":"10.1155\/2018\/4845894"},{"key":"999_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000356042","volume":"2","author":"L Bartalena","year":"2013","unstructured":"Bartalena L. Graves' orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2013;2:259\u201369.","journal-title":"Eur Thyroid J"},{"key":"999_CR21","first-page":"477","volume":"9","author":"S Abalkhail","year":"2003","unstructured":"Abalkhail S, Doi SA, Al-Shoumer KA. The use of corticosteroids versus other treatments for graves\u2019 ophthalmopathy: a quantitative evaluation. Med Sci Monit. 2003;9:477\u201383.","journal-title":"Med Sci Monit"},{"key":"999_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/EJE-07-0558","volume":"158","author":"RJ Van Geest","year":"2008","unstructured":"Van Geest RJ, Sasim IV, Koppeschaar HP, Kalmann R, Stravers SN, Bijlsma WR, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158:229\u201337.","journal-title":"Eur J Endocrinol"},{"key":"999_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1507\/endocrj.52.735","volume":"52","author":"S Kubota","year":"2005","unstructured":"Kubota S, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, et al. Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease. Endocr J. 2005;52:735\u201341.","journal-title":"Endocr J"},{"key":"999_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320\u201332.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-00999-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13052-021-00999-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-00999-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T07:28:44Z","timestamp":1614670124000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-021-00999-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1186\/s13052-021-00999-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-110598\/v1","asserted-by":"object"}]},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"31 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of was approved by Linyi People\u2019s Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}